Strong RSV Vaccine Results Gives GSK An Edge Over Rival Pfizer

But Competition Will Be Fierce

 
• By Andrew McConaghie
  
GSK House, August 2022
Employees at the GSK's HQ in London. Its RSV candidate could be a $2bn blockbuster, and has been boosted by the new efficacy data. • Source: GSK
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip